Robert Schoene

Dr. Robert Schoene


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in High Altitude Medicine & Biology
Verified
Journal Article
Closed access
ALAndrew M. Luks
Andrew M. Luks
LFLuanne Freer
Luanne Freer
CGColin K. Grissom
Colin K. Grissom
SMScott E. McIntosh
Scott E. McIntosh
RSRobert Schoene
Robert Schoene
PHPeter H. Hackett
Peter H. Hackett

19 October 2020 in Toxins
Verified
Journal Article
Open access
PDF file
ZAZiyad Ayyoub
Ziyad Ayyoub
ABAllison Brashear
Allison Brashear
MBMarta Banach
Marta Banach
RSRobert Schoene
Robert Schoene
WSWilliam Stringer
William Stringer
MBMitchell Brin
Mitchell Brin
Two randomized, placebo-controlled studies evaluated the pulmonary function safety of onabotulinumtoxinA (onabotA) for treatment of upper and/or lower limb spasticity. Patients with stable baseline respiratory status received one or two treatments with placebo, 240 U, or 360 U of onabotA. Pulmonary function tests, adverse events, and efficacy were measured at least every 6 weeks for 18 weeks (Study 1) or 30 weeks (Study 2). Study 1 enrolled 109 patients (n = 36–37/group) and Study 2 enrolled 155 patients (n = 48–54/group). Mean baseline forced vital capacity (FVC) was 76–78% of predicted per group in Study 1 and 71% of predicted per group in Study 2. In Study 1, change from baseline FVC values were significantly (p < 0.05) decreased vs. placebo at weeks 3 (240 U −57 mL vs. placebo +110 mL) and 12 (360 U −6 mL vs. +167 mL placebo). In Study 2, change from baseline FVC values were significantly decreased in the 360 U group vs. placebo at weeks 6 (−78 mL vs. +49 mL placebo), 13 (−60 mL vs. +119 mL placebo), 18 (−128 mL vs. +80 mL placebo), and 24 (−82 mL vs. +149 mL placebo). Individual pulmonary function-related adverse events were not correlated with PFT decreases. The most frequent pulmonary-related adverse events were nasopharyngitis (Study 1) and upper respiratory tract infection (Study 2). Ashworth scores were significantly improved at multiple time points in both studies. Injection of onabotA for spasticity in patients with decreased pulmonary function, at single and repeated doses of up to 360 U, was associated with small but statistically significant decreases in FVC or forced expiratory volume 1 s (FEV1) (>12% and 200 mL) that were subclinical and not correlated with any adverse clinical pulmonary events.

1 January 2010
Verified
Book Chapter
Closed access
LALewis Adams
Lewis Adams
AAAnthony J. Alberg
Anthony J. Alberg
RARichard K. Albert
Richard K. Albert
KAKurt H. Albertine
Kurt H. Albertine
DADevanand Anantham
Devanand Anantham
RZRichard L. ZuWallack
Richard L. ZuWallack